AJANTA PHARMA LTD. - 532331 - Board Meeting Intimation for Considering And Approving Results.
AJANTA PHARMA LTD.has informed BSE that the meeting of the Board of Directors of the Company is scheduled on 05/05/2023 ,inter alia, to consider and approve a. Audited Financial Results (consolidated & standalone) of the Company for the quarter and year ended 31st March 2023; and b. Audited Financial Statements (consolidated & standalone) for the year ended 31st March 2023. AJANTA PHARMA LTD. - 532331 - Completion Of Extinguishment Of 22,10,500 Paid Up Equity Shares Of Rs. 2 Each Of Ajanta Pharma Limited (The 'Company')
This is to inform you that the Company has extinguished 22,10,500 fully paid-up Equity Shares of Rs. 2 each. A copy of the letter dated April 20, 2023 of Central Depository Services (India) Limited confirming extinguishment of shares is enclosed herewith as Annexure A. A certificate signed by M/s. Link Intime India Private Limited, Mr. Alwyn D'Souza of M/s. Alwyn D'Souza & Co. (Secretarial Auditor of the Company) and the Company confirming that the extinguishment of 22,10,500 Equity Shares is in compliance with Regulations 11 of the SEBI Buyback Regulations is enclosed herewith as Annexure B. AJANTA PHARMA LTD. - 532331 - Disclosures under Reg. 29(2) of SEBI (SAST) Regulations, 2011
The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Yogesh M Agrawal & Others AJANTA PHARMA LTD. - 532331 - Post-Buyback Public Announcement Regarding Buyback Of Equity Shares Of Ajanta Pharma Limited By Way Of Tender Offer From Existing Shareholders
We wish to inform you that pursuant to Regulation 24(vi) of the Buyback Regulations, the Company has published a Post-Buyback public announcement dated April 19, 2023 in relation to the Buyback in Business Standard (English- All Editions), Business Standard (Hindi- All Editions), Navshakti (Marathi- Mumbai Edition) on Thursday, April 20, 2023. In this regard, please find enclosed copy of the Post-Buyback Public Announcement, as published in the aforesaid newspapers. AJANTA PHARMA LTD. - 532331 - Format of the Initial Disclosure to be made by an entity identified as a Large Corporate : Annexure A
Format of Initial Disclosure to be made by an entity identified as a Large Corporate. Sr. No. Particulars Details 1Name of CompanyAJANTA PHARMA LTD. 2CIN NO.L24230MH1979PLC022059 3 Outstanding borrowing of company as on 31st March / 31st December, as applicable (in Rs cr) 0.00 4Highest Credit Rating during the previous FY A1+ 4aName of the Credit Rating Agency issuing the Credit Rating mentioned in (4)CARE RATINGS LIMITED 5Name of Stock Exchange# in which the fine shall be paid, in case of shortfall in the required borrowing under the frameworkNSE We confirm that we are a Large Corporate as per the applicability criteria given under the SEBI circular SEBI/HO/DDHS/CIR/P/2018/144 dated November 26, 2018. No Name of the Company Secretary: Gaurang Shah Designation: VP Legal and Company Secretary EmailId: [email protected] Name of the Chief Financial Officer: Arvind Agrawal Designation: Chief Financial Officer EmailId: [email protected] Date: 17/04/2023 Note: In terms para of 3.2(ii) of the circular, beginning F.Y 2022, in the event of shortfall in the mandatory borrowing through debt securities, a fine of 0.2% of the shortfall shall be levied by Stock Exchanges at the end of the two-year block period. Therefore, an entity identified as LC shall provide, in its initial disclosure for a financial year, the name of Stock Exchange to which it would pay the fine in case of shortfall in the mandatory borrowing through debt markets. AJANTA PHARMA LTD. - 532331 - Compliance With Reg. 40(10) Of The Listing Regulations - Compliance Certificate
Pursuant to Regulation 40(10) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith a certificate from a Practicing Company Secretary for the year ended on 31st March 2023, the contents of which are self-explanatory. AJANTA PHARMA LTD. - 532331 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
We are pleased to enclose herewith certificate under regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended 31st March 2023 received from M/s. Link Intime India Private Limited, Registrar and Share Transfer Agent of the Company. AJANTA PHARMA LTD. - 532331 - Compliance Certificate - Regulation 7(3) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For FY 2023
Compliance Certificate - Regulation 7(3) of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for FY 2023 AJANTA PHARMA LTD. - 532331 - Closure of Trading Window
Pursuant to provisions of SEBI (Prohibition of Insider Trading) Regulations, 2015 as amended from time to time and 'Ajanta's Code of Conduct for Insiders', the Trading Window for dealing in securities of the Company shall remain closed for Designated Persons (as defined in the Code) from close of business hours of Friday, 31st March 2023 till 48 hours after the declaration of Financial Results of the Company for the quarter and year ended 31st March 2023. AJANTA PHARMA LTD. - 532331 - Submission Of Letter Of Offer
With reference to the captioned Buyback and in furtherance of our earlier intimation regarding submission of Public Announcement dated March 13, 2023 published on March 14, 2023, please find enclosed the Letter of Offer dated March 28, 2023 along with the Tender Forms for demat and physical shareholders, which are being dispatched by the Company to the Eligible Shareholders within two working days from the Record Date being March 24, 2023.